Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01029418

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma

A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma

Sponsor: National Cancer Centre, Singapore

Updated 5 times since 2017 Last updated: Apr 14, 2015 Started: Nov 30, 2009 Primary completion: Feb 28, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The phase II portion was not conducted due to funding issue.

Other terminated trials from National Cancer Centre, Singapore

See all terminations from National Cancer Centre, Singapore

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

A PHASE1/PHASE2 clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by National Cancer Centre, Singapore and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Centre, Singapore

Data source: National Cancer Centre, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore